

SPBP  
New Drug Exclusions - 1Q 2018

DRUG NAME	CHEMICAL NAME	COMMENTS
LUXTURNA	voretigene neparvovec-rzyl	Intraocular injection. Ophthalmic gene therapy. Indicated for treatment of retinal dystrophy.
SYMDEKO	tezacaftor	Cystic fibrosis products are not currently covered.